["{\n\"step_by_step_thinking\": \"The question is about Nivolumab (Opdivo) and whether it's a PD-L1 inhibitor. None of the provided documents mention Nivolumab (Opdivo) or PD-L1 inhibitors. The documents discuss immunotherapy in general, malignant melanomas, brain tumors, and solid tumors, but they don't specify any particular drug or mechanism. Therefore, we can't conclude that Nivolumab (Opdivo) is a PD-L1 inhibitor based on the provided information.\",\n\"answer_choice\": \"B\""]